Price
No data yet.
Social Signal Score
Analyst Ratings
17 analystsRevenue
$1.48MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Neal S. Walker
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 71
- Beta
- 0.80
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -0.44
Financials
Revenue
$1.48M+116.5%Net Income
$-18.51MEBITDA
$-18.41MFree Cash Flow
$-24.09MEPS (diluted)
$-0.12Shares Outstanding (diluted)
149.45M+538.9%Operating Expenses
$22.10MCash & Debt
$114.29MReturn of Capital
$0.00Revenue by Segment (annual)
$7.83MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $7.83M | $-64.92M | $-0.53 |
| 2024 | $18.72M | $-132.06M | $-1.71 |
| 2023 | $31.25M | $-88.48M | $-1.27 |
| 2022 | $29.75M | $-86.91M | $-1.33 |
| 2021 | $6.76M | $-90.86M | $-1.60 |
| 2020 | $6.48M | $-51.02M | $-1.20 |
| 2019 | $4.23M | $-161.35M | $-3.46 |
| 2018 | $10.09M | $-132.74M | $-4.03 |
| 2017 | $1.68M | $-68.52M | $-2.44 |
| 2016 | $0.00 | $-48.08M | $-2.25 |
| 2015 | $0.00 | $-20.56M | $-1.10 |
| 2014 | $0.00 | $-8.52M | $-0.80 |
| 2013 | $0.00 | $-5.24M | $-3.13 |
Valuation
ACRShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
38-24.00%Social Signal Score
Mentions (6)
- Newsbenzinga.com·5d ago·Negative
This Aclaris Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
View source ↗ - Newsbenzinga.com·6d ago·Neutral
Aclaris Therapeutics, Summit Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session U.S. stock futures were lower this morning, with the Nasdaq 100 futures falling over 1% on Monday.
View source ↗ - Newsseekingalpha.com·26d ago·Positive
Aclaris Therapeutics, Inc. (ACRS) Discusses ATI-052 Proof-of-Concept Results in Atopic Dermatitis and Asthma Transcript Aclaris Therapeutics, Inc. (ACRS) Discusses ATI-052 Proof-of-Concept Results in Atopic Dermatitis and Asthma Transcript
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
…Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants WAYNE, Pa., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced the pricing of an underwritten offering of 7,785,714 shares of its common stock at a price of $3.50 per share and, in lieu of shares of common stock to certain investors, pre-funded warra…
View source ↗ - Newszacks.com·68d ago·Neutral
Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock? Aclaris (ACRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
View source ↗ - Newszacks.com·104d ago·Positive
Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade The consensus price target hints at a 69.2% upside potential for Aclaris (ACRS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
View source ↗
Earnings
Thu, Feb 25(in 3 months)
Consensus estimate $-0.13 per share
Typical surprise +6.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$-0.12 vs $-0.16beat
- Thu, Aug 6$-0.15 vs $-0.16beat
- Thu, May 7$-0.15 vs $-0.16beat
- Thu, Feb 26$-0.16 vs $-0.15miss
- Thu, Nov 6$-0.12 vs $-0.13beat
- Thu, Aug 7$-0.13 vs $-0.13beat
Estimates and results for ACRS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ACRS officers and directors.
- Bought
- —
- Sold
- $1.4m
0 trades
1 trade
- Leonard Braden Michaelsold
99 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ACRS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
